Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance

Pediatric Nephrology

Volumn 20, Issue 7, 2005, Pages 989-993

  Bamgbola, Oluwatoyin F ^a   del Rio, Marcela ^b   Kaskel, Frederick J ^b   Flynn, Joseph T ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Adequacy; Adolescents; Children; Safety; Thrombolysis; Treatment outcome

Indexed keywords

ALTEPLASE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW; BLOOD VESSEL CATHETERIZATION; CLINICAL ARTICLE; DATA ANALYSIS; DEMOGRAPHY; FEMALE; HEMODIALYSIS; HUMAN; INFUSION; KAPLAN MEIER METHOD; MALE; OUTPATIENT CARE; PEDIATRICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; SCHOOL CHILD; THROMBOSIS; VASCULAR ACCESS; VASCULAR PATENCY; VENOUS PRESSURE;

ADOLESCENT; CATHETERS, INDWELLING; CHILD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 21344472135     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1797-1     Document Type: Article

References (28)

1. North American Pediatric Renal Transplant Cooperative Study (2002) Annual Report. EMMES Corporation, Potomac
2. Schwab SJ (1998) Hemodialysis vascular access: Entering a new era. Am J Kidney Dis 34:308-311
3. Tokars JI, Light P, Anderson J, Miller ER, Parrish J, Armistead N, Jarvis WR, Gehr T (2001) A prospective study of vascular access infections at seven-outpatient hemodialysis centers. Am J Kidney Dis 37:1232-1240
4. W0ood EG, Hand M, Briscoe DM, Donaldson MA, Yiu V, Harley FL, Warady BA, Ellis EN (2001) Risk factors for mortality in infants and young children on dialysis. Am J Kidney Dis 37:573-579
5. Choi M, Massicotte MP, Marzinotto V, Holmes JL, Andrew M (2001) The use of altepase to restore patency of central venous lines in pediatric patients: A cohort study. J Pediatr 139:152-156
6. Ng R, Li X, Tu T, Semba CP (2004) Altepase for treatment of occluded peripherally inserted catheters: Safety and efficacy in 240 patients. J Vasc Interv Radiol 15 45-49
7. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP (2002) Safety and efficacy of altepase for restoring function in occluded central venous catheters: Results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 20:317-324
8. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER (2001) Recombinant tissue plasminogen activator (altepase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to open Occluded Lines (COOL) efficacy trial. J Interv Radiol 12:951-955
9. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER (2002) Treatment of occluded central venous catheters with altepase: Results in 1,064 patients. J Interv Radiol 13:1199-1205
10. Shen V, Li X, Murdock M, Resnansky L, McCluskey ER, Semba CP (2003) Recombinant tissue plasminogen activator (altepase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol 25:38-45
11. Wang M, Hays T, Balasa V, Bagtell R, Gruppo R, Grabowski EF, Valentino LA, Tsao-Wu G, Manco-Johnson MJ (2003) Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 25:379-386
12. Savader SJ, Ehrman KO, Porter DJ, Haikal LC, Oteham AC (2001) Treatment of hemodialysis catheter-associated fibrin sheaths by r-tPA infusion: critical analysis of 124 procedures. J Vasc Interv Radiol 12:711-715
13. Grunwald MR, Hofmann LV (2004) Comparison of urokinase, altepase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol 15:347-352
14. Sugimoto K, Hofmann LV, Razavi MK, Kee ST, Sze DY, Dake MD, Semba CP (2003) The safety, efficacy, and pharmacoeconomics of low-dose altepase compared with urokinase for catheter-directed thrombolysis and venous occlusions. J Vasc Surg 37:512-517
15. Daeihagh P, Jordan J, Chen GJ, Rocco M (2000) Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36:75-79
16. Schenk P, Rosenkranz AR, Wolfl G, Horl WH, Traindl O (2000) Recombinant tissue plasminogen activator is useful alternative to heparin in priming Quinton Permcath. Am J Kidney Dis 35:130-136
17. Schwab SJ, Butterfly D (1999) Reducing the risk of hemodialysis access (1999). Am J Kidney Dis 34:362-363
18. Haire WD, Atkinson JB, Stephens LC, Kotulak GD (1994) Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 72:543-547
19. Kanamasa K, Inoue Y, Otami N, Naito N, Morii H, Ikeda A, Taniguchi M, Ishida N, Hayashi T, Ishikawa K (2001) tPA via infusion catheters followed by continuous IV infusion for three days prevents intimal hyperplasia after balloon injury. Angiology 52: 819-825
20. Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of activation of plasminogen by human tissue plasminogen activator: Role of fibrin. J Biol Chem 257:2912-2919
21. Rodgers GM (1999) Thrombosis and anti-thrombotic therapy. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds) Wintrobe's clinical hematology. Williams and Wilkins, Baltimore, MD, pp 1781-1810
22. Shaffer D, Madras PN, Williams ME, D'Elia JA, Kaldany A, Monaco AP (1998) Use of Dacron cuffed silicone catheters as long-term hemodialysis access. ASAIO J 38:55-58
23. Garella S (1997) The cost of dialysis in the USA. Nephrol Dial Transplant 12:10-21
24. Hassell DRM, van der Sande FM, Kooman JP, Tordoir JP, Leunissen KML (2001) Optimizing dialysis dose by increasing blood flow rate in patients with reduced vascular-access flow rate. Am J Kidney Dis 38:948-955
25. Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM (2003) Altepase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 37:27-33
26. Terrill KR, Lemons RS, Goldsby RE (2003) Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol 25:864-867
27. Hyman G, England M, Kibede S, Lee P, Willets G (2004) The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center. Nephrol Clin Pract 96:c39-c42
28. Hillerman DE, Dunlay RW, Packard KA (2003) Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 23:137-141